You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

CLINICAL TRIALS PROFILE FOR BESIVANCE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Besivance

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00347932 ↗ A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. Completed Bausch & Lomb Incorporated Phase 3 2006-06-01 Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.
NCT00824070 ↗ Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects Completed Bausch & Lomb Incorporated Phase 1 2009-02-01 This study is being conducted to assess the concentration of besifloxacin, moxifloxacin, or gatifloxacin in aqueous humor samples collected following topical instillation of the associated formulation in subjects undergoing cataract surgery.
NCT00905762 ↗ Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation Completed Bausch & Lomb Incorporated Phase 1 2009-03-01 The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days.
NCT00924729 ↗ Study of Ocular Penetration of Topically Administered Fluoroquinolones Completed Johns Hopkins University Phase 4 2009-09-01 This study is being conducted to evaluate the intraocular penetration of Moxifloxacin 0.5% ophthalmic solution (Vigamox) and Besifloxacin 0.6% ophthalmic suspension (Besivance) after pre-operative topical administration in subjects undergoing cataract surgery.
NCT00972777 ↗ Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Completed Bausch & Lomb Incorporated Phase 2/Phase 3 2009-10-01 This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Besivance

Condition Name

Condition Name for Besivance
Intervention Trials
Bacterial Conjunctivitis 4
Cataract Extraction 2
Acute Bacterial Conjunctivitis 1
Blepharitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Besivance
Intervention Trials
Conjunctivitis, Bacterial 5
Conjunctivitis 5
Cataract 4
Lacrimal Duct Obstruction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Besivance

Trials by Country

Trials by Country for Besivance
Location Trials
United States 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Besivance
Location Trials
New York 6
New Jersey 2
Kentucky 1
Missouri 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Besivance

Clinical Trial Phase

Clinical Trial Phase for Besivance
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Besivance
Clinical Trial Phase Trials
Completed 10
Terminated 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Besivance

Sponsor Name

Sponsor Name for Besivance
Sponsor Trials
Bausch & Lomb Incorporated 10
Frank A. Bucci, Jr., M.D. 1
Rutgers, The State University of New Jersey 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Besivance
Sponsor Trials
Industry 12
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Besivance: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction

Besivance, a fluoroquinolone antibiotic eye drop, is marketed by Bausch and Lomb for the treatment of bacterial conjunctivitis. This article delves into the clinical trials, market analysis, and future projections for Besivance.

Clinical Trials and Efficacy

Study Design and Outcomes

The efficacy of Besivance in treating bacterial conjunctivitis has been established through several clinical trials. These include two Phase III studies (Studies 433 and 434) and one Phase II study (Study 373), all of which were multicenter, randomized, double-masked, parallel-group studies. Two of these studies were vehicle-controlled, while the third used an active comparator, moxifloxacin hydrochloride ophthalmic solution 0.5%[1][4].

Microbial Eradication and Clinical Resolution

The trials demonstrated that Besivance was more effective than the vehicle and non-inferior to the active comparator. Specifically, Besivance showed high microbial eradication rates, including against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE), even in cases where these isolates were resistant to ciprofloxacin[4].

Safety and Tolerability

Besivance was generally well-tolerated in these studies, with safety and efficacy evaluated in patients one year of age and older. The drug's safety and effectiveness in infants below one year of age have not been established[1][4].

Mechanism of Action

Besivance contains besifloxacin hydrochloride, a fluoroquinolone antibiotic that inhibits both bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for bacterial DNA replication, transcription, and repair, making besifloxacin effective against a broad spectrum of Gram-positive and Gram-negative bacteria[1].

Market Analysis

Current Market Position

Besivance is part of the broader ophthalmic therapeutics market, which was estimated at USD 37.82 billion in 2023 and is projected to grow at a CAGR of 8.34% from 2024 to 2030. The increasing prevalence of eye-related disorders is a significant driver of this market growth[5].

Patent and Regulatory Landscape

Besivance is protected by four patents, with the earliest generic entry date estimated to be January 9, 2031, subject to patent challenges or generic licensing. This extended exclusivity period provides a competitive advantage for Bausch and Lomb in the market[2].

Global Sales and Market Penetration

While specific global sales figures for Besivance are not publicly available, the drug benefits from being part of a well-established brand portfolio. The presence of a strong distribution network of clinical laboratories and hospitals, particularly in regions like Asia Pacific, enhances market penetration[2][5].

Market Projections

Growth Drivers

The ophthalmic drugs market is driven by the increasing prevalence of eye-related disorders such as macular degeneration, diabetic retinopathy, and presbyopia. The Asia Pacific region is expected to witness the fastest growth due to rising consumer awareness and the development of novel technologies in countries like China and India[5].

Competitive Landscape

Besivance competes in a market dominated by anti-VEGF agents, which accounted for 32.71% of the global revenue in 2023. However, its broad-spectrum activity and efficacy against resistant bacteria like MRSA and MRSE position it as a valuable option in the treatment of bacterial conjunctivitis[5].

Future Trends

The market is expected to see increased research activities and the introduction of novel drugs. For Besivance, maintaining its market share will depend on continued clinical evidence supporting its efficacy and safety, as well as strategic marketing and distribution efforts[3][5].

Recent Clinical Trials and Research

Ongoing Studies

Recent clinical trials include Phase 4 studies sponsored by Ocular Therapeutix, Inc., and Sight Medical Doctors PLLC, among others. These studies continue to evaluate the long-term efficacy and safety of Besivance in various patient populations[2].

Post-Marketing Surveillance

Post-marketing surveillance and real-world data collection are crucial for understanding the long-term impact of Besivance. These data help in refining treatment guidelines and ensuring the drug's continued safety and efficacy in real-world settings[3].

Key Takeaways

  • Efficacy and Safety: Besivance has demonstrated efficacy in treating bacterial conjunctivitis, including cases involving resistant bacteria, and is generally well-tolerated.
  • Market Position: It is part of the growing ophthalmic therapeutics market, protected by patents until 2031.
  • Growth Drivers: Increasing prevalence of eye-related disorders and strong market penetration in regions like Asia Pacific.
  • Competitive Landscape: Competes with anti-VEGF agents but maintains a strong position due to its broad-spectrum activity.
  • Future Trends: Continued clinical evidence and strategic marketing will be crucial for maintaining market share.

FAQs

What is Besivance used for?

Besivance is used for the treatment of bacterial conjunctivitis caused by susceptible isolates of various bacteria, including MRSA and Pseudomonas aeruginosa.

What is the mechanism of action of Besivance?

Besivance works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication, transcription, and repair.

What are the key findings from the clinical trials of Besivance?

Clinical trials have shown that Besivance is more effective than the vehicle and non-inferior to the active comparator, moxifloxacin, with high microbial eradication rates and good safety and tolerability profiles.

When is the generic entry date for Besivance estimated?

The generic entry date for Besivance is estimated to be January 9, 2031, subject to patent challenges or generic licensing.

What are the growth drivers for the ophthalmic therapeutics market?

The growth drivers include the increasing prevalence of eye-related disorders, rising consumer awareness, and the development of novel technologies in regions like Asia Pacific.

Sources

  1. Summary Basis of Decision for Besivanceā„¢ - Health Canada
  2. BESIVANCE Drug Patent Profile - DrugPatentWatch
  3. Antimicrobial Drugs Market Returns Analysis - ASPE
  4. In Vitro Potency and Broad-spectrum Activity for the Treatment - Bausch & Lomb
  5. Ophthalmic Drugs Market Size & Share | Industry Report 2030 - Grand View Research

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.